Sage Therapeutics filings document a brain-health biopharmaceutical issuer and its public-company transition, including Form 25 removal of its common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting obligations. The records identify the covered security as common stock and reflect the company’s reduced holder-of-record status at the time of deregistration.
Company 8-K filings also record material events, financial-results releases, capital-structure disclosures, governance matters, and transaction-related disclosures. Earlier operating disclosures covered ZURZUVAE collaboration revenue, pipeline programs such as SAGE-319, clinical and regulatory topics, risk factors, and business updates for the company’s brain-health drug development and commercialization activities.